The sale is small relative to market cap and appears to be a routine compensation-related transaction. Monitor for any additional insider selling patterns or changes in insider holdings in upcoming Form 4 filings.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $42.61entry
- T+1 · 8d ago +0.84%α −1.52% · $42.97
- T+5 · 4d ago +4.44%α +1.84% · $44.50
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Mark Sabag, Executive VP of International Markets Commercial at Teva, filed a Form 144 notice of intent to sell 46,000 ordinary shares valued at approximately $1.93 million, based on an indicative market price of $41.93 per share. The sale is tied to a stock option exercise and compensation, representing a routine insider sale for tax or diversification purposes.
Key Facts
- Insider: Mark Sabag, Executive VP International Markets Commercial
- Shares to be sold: 46,000 ordinary shares
- Approximate value: $1,928,728.30 (based on indicative price of $41.928876)
- Broker: Citigroup Global Markets Inc.
- Sale type: Stock option exercise and sale, compensation-related
- Filing date: November 5, 2026
- Company market cap: $48.8B
- Sale value represents ~0.004% of market cap
Financial Impact
Sale of 46,000 shares worth ~$1.93M, representing about 0.004% of Teva's $48.8B market cap
Risk Factors
- Insider sale may signal personal liquidity needs or tax planning, not necessarily a bearish view
- Form 144 is an intent to sell; the actual sale may not occur
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001973379-26-000362 |
| Document: 0001973379-26-000362-index.html | 0001973379-26-000362 |
| Document: 0001973379-26-000362.txt | 0001973379-26-000362 |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Viewing Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers